vorinostat has been researched along with Anorexia in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat-XP is a feasible first-line chemotherapy for patients with advanced GC." | 2.82 | Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. ( Kang, YK; Lee, CW; Na, YS; Ryoo, BY; Ryu, MH; Yoo, C, 2016) |
| " One week later, daily vorinostat dosing was begun and continued until toxicity or disease progression occurred." | 2.75 | Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. ( Belani, CP; Beumer, JH; Egorin, MJ; Harvey, RD; Holleran, J; Ivy, SP; Kummar, S; Lin, Y; LoRusso, P; Ramalingam, SS; Sarantopoulos, J; Shibata, S; Yerk, M, 2010) |
| "Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients." | 2.73 | Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. ( Blumenschein, GR; Chen, C; Chiao, JH; Frankel, SR; Kies, MS; Kumar, AJ; Lu, C; Papadimitrakopoulou, VA; Ricker, JL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoo, C | 1 |
| Ryu, MH | 1 |
| Na, YS | 1 |
| Ryoo, BY | 1 |
| Lee, CW | 1 |
| Kang, YK | 1 |
| Ramalingam, SS | 1 |
| Kummar, S | 1 |
| Sarantopoulos, J | 1 |
| Shibata, S | 1 |
| LoRusso, P | 1 |
| Yerk, M | 1 |
| Holleran, J | 1 |
| Lin, Y | 1 |
| Beumer, JH | 1 |
| Harvey, RD | 1 |
| Ivy, SP | 1 |
| Belani, CP | 1 |
| Egorin, MJ | 1 |
| Blumenschein, GR | 1 |
| Kies, MS | 1 |
| Papadimitrakopoulou, VA | 1 |
| Lu, C | 1 |
| Kumar, AJ | 1 |
| Ricker, JL | 1 |
| Chiao, JH | 1 |
| Chen, C | 1 |
| Frankel, SR | 1 |
3 trials available for vorinostat and Anorexia
| Article | Year |
|---|---|
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Topics: Acetylation; Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Topics: Anorexia; Antineoplastic Agents; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Fatig | 2010 |
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Capsules; Car | 2008 |